Investigation on colistin use at the University Medical Center Hochiminh City

Abstract

Antibiotic resistance has turned into a global crisis, with pathogens being less susceptible or even resistant to last-resort antibiotics. In 2010, Lim LM estimated that no new antibiotics with activity against multidrug-resistant (MDR) gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter baumanii and Klebsiella pneumoniae are expected to be released within the next five years 1. This high lights the role of colistin, an old-class antibiotic that still remains the last-line therapy in clinical settings. The spread of colistin use has recently raised concerns about resistance to this antibiotic.